Please login to the form below

Not currently logged in
Email:
Password:

cancer drug

This page shows the latest cancer drug news and features for those working in and with pharma, biotech and healthcare.

FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer

FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer

The drug has been granted accelerated approval, and the companies have also released positive data on first-line treatment. ... US. The Food and Drug Administration (FDA) has approved the antibody-drug conjugate Tivdak (tisotumab vedotin-tftv) for

Latest news

More from news
Approximately 7 fully matching, plus 1,217 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 48 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    stage prostate cancer, with the hope of curing more men of the disease.”. ... Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a ... world class cancer institute and being a

  • Incanthera appoints Laura Brogden as CFO Incanthera appoints Laura Brogden as CFO

    She joins from Summ.it. Drug development and targeted cancer medicines group Incanthera has appointed Laura Brogden as its new chief financial officer.

  • Former Novartis exec joins Genmab Former Novartis exec joins Genmab

    cancer drug Afinitor. ... She has a strong track record and skills in cancer drug development which will further strengthen the company as we build a winning team to continue our success in the future

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...